Mina Mar Marketing – Blog & Announcements

TORONTO, Feb 09, 2010 /PRNewswire via COMTEX/ — Hard to Treat Diseases (HTDS; www.htdsmedical.com), continuing on the company’s announcement from the January 22, 2010, where the company announced a targeted merger with a medical company from Middle East, HTDS is using this opportunity to inform the public that as the merger negotiations progress at a good pace. The company amended its share structure to accommodate the merger.

HTDS increased the number of its authorized shares to 8.8 billion to accommodate the merger and the size of the new medical company from middle east/Israel, and expand the Melem Secrets cosmetics line. HTDS will publish full details about the new company as soon as both sides finalize the merger. Filings from Florida State are filed with Pink Sheets. Obviously if the merger does not happen the stock will be returned to the treasury of HTDS.

The new merger candidate operates an obstetrician type medical company. This Middle Eastern company focuses on treatment of pre-term labor and induction of labor. The company seeks cooperation with HTDS to co-develop this enzyme and meet GMP and FDA enzyme/cytokines production; as well as to develop Phase II clinical trials in China and share production and marketing with HTDS.

Pre-term birth affects 11 percent of births in the USA each year, and accounts for 75% of infant deaths and 50% of the long-term neurological handicaps, including cerebral palsy, blindness, deafness, and developmental defects. The direct care in Neonatal Intensive Care Units (NICU) costs staggering $45 billion to $65 billion in the developed world, treating an estimated 1.5 million pre-term infants, with total of about 4.5 million NICU hospitalization weeks.

To be included in HTDS’ email database for press releases and industry updates, please subscribe at or opt in with your email address at this link: http://www.minamargroup.com/updates/.